Combined CV787 and Taxotere for advanced prostate cancer
Researchers at US firm Calydon have reported a novel therapeuticstrategy for treating advance prostate cancer that combines a genetically-modified adenovirus, CV787, with taxone chemotherapeutic agents. Calydon plans to test the combination therapy in a Phase I/II clinical trial early this year.
In their study, reported in Cancer Research (January 15), the Calydon researchers, using an animal model of human prostate cancer, demonstrated a significant antitumor effect and the potential for a single-dose curative therapeutic. The combination of the taxanes, Taxol (paclitaxel; Bristol-Myers Squibb) and Taxotere (docetaxel; Aventis) and Calydon's CV787 created a wide 1,000:1 window of efficacy without toxicity in a mouse model, and the researchers believe that the combination of CV787 and docetaxel could be used to effectively treat patients with metastatic prostate cancer.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze